Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about breast cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in
Breast Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Overview
Factors Associated with Increased Risk of Breast Cancer
Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Ductal Carcinoma In Situ
IntroductionDuctal carcinoma in situ (DCIS) is a noninvasive condition. DCIS can progress to become invasive cancer, but estimates of the likelihood of this vary widely. Some people include DCIS in breast cancer statistics. The frequency of the diagnosis of DCIS has increased markedly in the United States since the widespread use of screening mammography. In 1998, DCIS accounted for about 18% of all newly diagnosed invasive plus noninvasive breast tumors in the United States. Very few cases of DCIS present as a palpable mass; 80% are diagnosed by mammography alone. DCIS comprises a heterogeneous group of histopathologic lesions that have been classified into several subtypes based primarily on architectural pattern: micropapillary, papillary, solid, cribriform, and comedo. Comedo-type DCIS consists of cells that appear cytologically malignant, with the presence of high-grade nuclei, pleomorphism, and abundant central luminal necrosis. Comedo-type DCIS appears to be more aggressive,
Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IIIB, Inoperable IIIC, IV, Recurrent, and Metastatic Breast Cancer
Inoperable Stage IIIB or IIIC or Inflammatory Breast CancerMultimodality therapy delivered with curative intent is the standard of care for patients with clinical stage IIIB disease. In a retrospective series, approximately 32% of patients with ipsilateral supraclavicular node involvement and no evidence of distant metastases (pN3c) had prolonged disease-free survival (DFS) at 10 years with combined modality therapy. Although these results have not been replicated in another series, this result suggests such patients should be treated with the same intent. Initial surgery is generally limited to biopsy to permit the determination of histology, estrogen-receptor (ER) and progesterone-receptor (PR) levels, and human epidermal growth factor receptor 2 (HER2/neu) overexpression. Initial treatment with anthracycline-based chemotherapy and/or taxane-based therapy is standard.[2,3] In one series of 178 patients with inflammatory breast cancer, DFS
Male Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Options for Male Breast Cancer
Initial Surgical ManagementPrimary standard treatment is a modified radical mastectomy with axillary dissection.[1,2,3] Responses are generally similar to those seen in women with breast cancer. Breast conservation surgery with lumpectomy and radiation therapy has also been used and results have been similar to those seen in women with breast cancer. (Refer to the PDQ summary on Breast Cancer Treatment for more information.)Adjuvant TherapyIn men with node-negative tumors, adjuvant therapy should be considered on the same basis as for a woman with breast cancer since there is no evidence that response to therapy is different for men or women.In men with node-positive tumors, both chemotherapy plus tamoxifen and other hormonal therapy have been used and can increase survival to the same extent as in women with breast cancer. Currently, no controlled studies have compared adjuvant treatment options. Approximately 85% of all male breast cancers are estrogen
Genetics of Breast and Ovarian Cancer (PDQ®): Genetics - Health Professional Information [NCI] - High-Penetrance Breast and / or Ovarian Cancer Susceptibility Genes
BRCA1andBRCA2IntroductionEpidemiologic studies have clearly established the role of family history as an important risk factor for both breast and ovarian cancer. After gender and age, a positive family history is the strongest known predictive risk factor for breast cancer. However, it has long been recognized that in some families, there is hereditary breast cancer, which is characterized by an early age of onset, bilaterality, and the presence of breast cancer in multiple generations in an apparent autosomal dominant pattern of transmission (through either the maternal or paternal lineage), sometimes including tumors of other
Breast Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Breast Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Breast Cancer
For more information from the National Cancer Institute about breast cancer, see the following: Breast Cancer Home PageWhat You Need to Know About™ Breast CancerSurgery Choices for Women with DCIS or Breast CancerPreventive MastectomyBreast Reconstruction After MastectomyAdjuvant and Neoadjuvant Therapy for Breast CancerSentinel Lymph Node BiopsyDrugs Approved for Breast CancerHormone Therapy for Breast CancerUnderstanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies and Targeted Therapies for Breast Cancer)Targeted Cancer TherapiesInflammatory Breast CancerBRCA1 and BRCA2: Cancer Risk and Genetic TestingGenetic Testing for Hereditary Cancer SyndromesFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with
Breast Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Breast Cancer
Treatment of recurrent breast cancer (cancer that has come back after treatment) in the breast or chest wall may include the following:Surgery (modified radical mastectomy), radiation therapy, or both.Chemotherapy or hormone therapy.Antibody-drug conjugate therapy with ado-trastuzumab emtansine.A clinical trial of trastuzumab combined with chemotherapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent breast cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Breast Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?
Cancer prevention is action taken to lower the chance of getting cancer.